sar425899 sanofi dual glp-1 glucagon agonist Receptor occupancy of glucagon-like peptide 1/glucagon receptor in individuals with type 2 diabetes Design of Novel Exendin-Based Dual
Description
Clinical Evidence on GLP-1, Dual, and Triple Agonists in Adolescents The clinical evidence surrounding GLP-1RAs and their dual and triple agonist counterparts has grown significantly in recent years
Patients now have more flexibility to choose between injectable or oral GLP-1 treatment options
doi:10.1007/s11154-016-9373-0 116
Liver disease: Regular liver tests are important
References 1 MuscogiuriGCignarelliAGiorginoFProdramFSantiDTirabassiGet al
Long-lasting: While minor touch-ups are sometimes needed, results can last for years when weight remains stable
